The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus

Journal of Interferon and Cytokine Research

Volumn 31, Issue 10, 2011, Pages 781-789

  Davis, Laurie S ^a   Hutcheson, Jack ^a,b   Mohan, Chandra ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NNC 0152 0000 0001; RONTALIZUMAB; SIFALIMUMAB; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; FEVER; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTOPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL;

ADAPTIVE IMMUNITY; ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 80054709328     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0047     Document Type: Article

References (99)

1. Aggarwal BB. 2003. Signalling pathways of the TNF superfam-ily: A double-edged sword. Nat Rev Immunol 3:745-756. (Pubitemid 41070815)
2. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, Arinobu Y, Yamaoka K, Niiro H, Shinozaki M, Hirakata H, Horiuchi T, Otsuka T, Niho Y. 1999. Th1/Th2 balance of peripheral T helper cells in systemic lupus er-ythematosus. Arthritis Rheum 42:1644-1648. (Pubitemid 30263632)
3. al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S. 1993. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 13:58-67. (Pubitemid 23047997)
4. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. 2009. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48:1451-1454.
5. Aringer M, Smolen JS. 2008. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 10:202.
6. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2610-2615. (Pubitemid 36297546)
7. Bave U, Vallin H, Alm GV, Ronnblom L. 2001. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 17:71-80. (Pubitemid 32751883)
8. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Ronnblom L. 2000. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9:664-671. (Pubitemid 32011791)
9. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197:711-723. (Pubitemid 36350866)
10. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540-1543. (Pubitemid 33063928)
11. Braun D, Geraldes P, Demengeot J. 2003. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 20:15-25. (Pubitemid 36207624)
12. Brugos B, Kiss E, Dul C, Gubisch W, Szegedi G, Sipka S, Zeher M. 2010. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum Immunol 71:874-877.
13. Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC 3rd, Leonard WJ, Roopenian DC. 2009. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 106:1518-1523.
14. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A. 2010. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 37:60-70.
15. Chan AC. 2011. B cell immunotherapy in autoimmunity-2010 update. Mol Immunol 48:1344-1347.
16. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. 2010. Ba-sophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 16:701-707.
17. Croft M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9:271-285.
18. Crow MK. 2008. Collaboration, genetic associations, and lupus erythematosus. N Engl J Med 358:956-961. (Pubitemid 351397097)
19. Crow MK, Kirou KA, Wohlgemuth J. 2003. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36:481-490. (Pubitemid 37498244)
20. Davidson A. 2010. Targeting BAFF in autoimmunity. Curr Opin Immunol 22:732-739.
21. Dinarello CA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720-3732.
22. Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C. 2009. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glo-merulonephritis. J Immunol 183:6831-6838.
23. Fu Y, Xie C, Yan M, Li Q, Joh JW, Lu C, Mohan C. 2005. The lipopolysaccharide-triggered mesangial transcriptome: Evaluating the role of interferon regulatory factor-1. Kidney Int 67:1350-1361. (Pubitemid 40463111)
24. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, Gunnarsson I, Svenungsson E, Padyukov L, Sturfelt G, Jonsen A, Bengtsson AA, Rantapaa-Dahlqvist S, Baechler EC, Brown EE, Alarcon GS, Edberg JC, Ramsey-Goldman R, McGwin G, Jr., Reveille JD, Vila LM, Kimberly RP, Manzi S, Petri MA, Lee A, Gregersen PK, Seldin MF, Ronnblom L, Criswell LA, Syvanen AC, Behrens TW, Graham RR. 2009. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41:1228-1233.
25. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, Smyth MJ, Mackay CR, Mackay F. 2007. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204:1959-1971. (Pubitemid 47236330)
26. Haas C, Ryffel B, Le Hir M. 1998. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 160:3713-3718. (Pubitemid 28176072)
27. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. 2008. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 181:2211-2219.
28. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, James JA, Merrill JT, Gilkeson GS, Seldin MF, Yin H, Baechler EC, Li QZ, Wakeland EK, Bruner GR, Kaufman KM, Kelly JA. 2008. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in IT-GAM, PXK, KIAA1542 and other loci. Nat Genet 40:204-210. (Pubitemid 351171405)
29. Hasegawa K, Hayashi T, Maeda K. 2002. Promotion of lupus in NZB x NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4. J Comp Pathol 127:1-6.
30. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 178:3822-3830. (Pubitemid 46417651)
31. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. 1979. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301:5-8. (Pubitemid 9226519)
32. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, De-vogelaer JP, Renauld JC. 1995. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4:393-395.
33. Hron JD, Peng SL. 2004. Type I IFN protects against murine lupus. J Immunol 173:2134-2142. (Pubitemid 38971652)
34. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. 2010. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542-552.
35. Iwano M, Dohi K, Hirata E, Kurumatani N, Horii Y, Shiiki H, Fukatsu A, Matsuda T, Hirano T, Kishimoto T, and others. 1993. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 40:16-21. (Pubitemid 23221728)
36. Jacob CO, van der Meide PH, McDevitt HO. 1987. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 166:798-803. (Pubitemid 18013554)
37. Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, Thomas JA, Reiff A, Myones BL, Ojwang JO, Kaufman KM, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Silverman E, Ziegler J, Kelly JA, Merrill JT, Harley JB, Ramsey-Goldman R, Vila LM, Bae SC, Vyse TJ, Gilkeson GS, Gaffney PM, Moser KL, Langefeld CD, Zidovetzki R, Mohan C. 2009. Identification of IRAK1 as a risk gene with critical role in the patho-genesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 106:6256-6261.
38. Jones SA. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175:3463-3468. (Pubitemid 41292002)
39. Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO, Jolly M, Crow MK, Skol AD, Niewold TB. 2010. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 12:R151.
40. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. 2009. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182:34-38.
41. Kariuki SN, Niewold TB. 2010. Genetic regulation of serum cyto-kines in systemic lupus erythematosus. Transl Res 155:109-117.
42. Katz U, Zandman-Goddard G. 2010. Drug-induced lupus: an update. Autoimmun Rev 10:46-50.
43. Khan WN. 2009. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 183:3561-3567.
44. Kim K, Cho SK, Sestak A, Namjou B, Kang C, Bae SC. 2010. Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis 69:1247-1250.
45. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. 2005. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52:1491-1503. (Pubitemid 40663941)
46. Kono DH, Balomenos D, Park MS, Theofilopoulos AN. 2000. Development of lupus in BXSB mice is independent of IL-4. J Immunol 164:38-42. (Pubitemid 30012969)
47. Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 Cells. Annu Rev Immunol 27:485-517.
48. Kumar KR, Li L, Yan M, Bhaskarabhatla M, Mobley AB, Nguyen C, Mooney JM, Schatzle JD, Wakeland EK, Mohan C. 2006. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 312:1665-1669. (Pubitemid 43902668)
49. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. 2006. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus er-ythematosus. Immunology 119:296-305. (Pubitemid 44571047)
50. Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL, Schwartzberg PL, Cook MC, Walters GD, Vinuesa CG. 2009. Follicular helper T cells are required for systemic autoimmu-nity. J Exp Med 206:561-576.
51. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D. 2000. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790-1800.
52. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839-844.
53. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. 2004. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 50:1861-1872. (Pubitemid 38725099)
54. Mackay F, Schneider P. 2009. Cracking the BAFF code. Nat Rev Immunol 9:491-502.
55. Malide D, Russo P, Bendayan M. 1995. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 26:558-564.
56. Moosig F, Zeuner R, Renk C, Schroder JO. 2004. IL-1RA in refractory systemic lupus erythematosus. Lupus 13:605-606. (Pubitemid 39145491)
57. Munoz-Valle JF, Vazquez-Del Mercado M, Garcia-Iglesias T, Orozco-Barocio G, Bernard-Medina G, Martinez-Bonilla G, Bastidas-Ramirez BE, Navarro AD, Bueno M, Martinez-Lopez E, Best-Aguilera CR, Kamachi M, Armendariz-Borunda J. 2003. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol 131:377-384. (Pubitemid 36205153)
58. Nagy G, Pallinger E, Antal-Szalmas P, Aleksza M, Marschalko M, Brozik M, Falus A, Gergely P. 2000. Measurement of in-tracellular interferon-gamma and interleukin-4 in whole blood T lymphocytes from patients with systemic lupus er-ythematosus. Immunol Lett 74:207-210.
59. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. 2007. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8:492-502. (Pubitemid 47365615)
60. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. 2008. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus er-ythematosus patients. Arthritis Rheum 58:2481-2487.
61. Nishimoto N, Kishimoto T. 2006. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619-626. (Pubitemid 44650950)
62. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. 2005. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64: 630-633. (Pubitemid 40469097)
63. Ouyang W, Kolls JK, Zheng Y. 2008. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454-467. (Pubitemid 351471762)
64. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. 2005. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102:3372-3377. (Pubitemid 40328052)
65. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. 1998. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16:283-288. (Pubitemid 28219167)
66. Peterson E, Robertson AD, Emlen W. 1996. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 5:571-575. (Pubitemid 27035726)
67. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Er-lander MG, Jackson MR, Winchester RJ. 2004. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glo-meruli. J Clin Invest 113:1722-1733. (Pubitemid 39071664)
68. Richaud-Patin Y, Alcocer-Varela J, Llorente L. 1995. High levels of TH2 cytokine gene expression in systemic lupus er-ythematosus. Rev Invest Clin 47:267-272.
69. Rochman Y, Spolski R, Leonard WJ. 2009. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480-490.
70. Ronnblom L, Alm GV. 2001a. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22:427-431. (Pubitemid 32709976)
71. Ronnblom L, Alm GV. 2001b. A pivotal role for the natural in-terferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 194:F59-F63. (Pubitemid 34028649)
72. Ronnblom L, Elkon KB. 2010. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 6:339-347.
73. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. 2002. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169:4314-4321. (Pubitemid 35178204)
74. Sabat R. 2010. IL-10 family of cytokines. Cytokine Growth Factor Rev 21:315-324.
75. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN. 2003. Type-I in-terferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197:777-788. (Pubitemid 36350872)
76. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR, James JA, Merrill JT, Lipsky P, Harley JB. 2008. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67:458-461. (Pubitemid 351498423)
77. Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR. 1998. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 161:494-503. (Pubitemid 28285560)
78. Shimizu S, Sugiyama N, Masutani K, Sadanaga A, Miyazaki Y, Inoue Y, Akahoshi M, Katafuchi R, Hirakata H, Harada M, Hamano S, Nakashima H, Yoshida H. 2005. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 175:7185-7192. (Pubitemid 41713412)
79. Shiroiwa W, Tsukamoto K, Ohtsuji M, Lin Q, Ida A, Kodera S, Ohtsuji N, Nakamura K, Tsurui H, Kinoshita K, Nishimura H, Shirai T, Hirose S. 2007. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus. Int Immunol 19:175-183. (Pubitemid 46179012)
80. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Ronnblom L, Syvanen AC. 2005. Polymorphisms in the tyrosine kinase 2 and inter-feron regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76:528-537. (Pubitemid 40250533)
81. Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, Jacob CO. 2003. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 170:4818-4825. (Pubitemid 36519992)
82. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Ro-vensky J, Alecock E, Woodworth T, Alten R. 2008. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987-997. (Pubitemid 351392039)
83. Strengell M, Julkunen I, Matikainen S. 2004. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 76:416-422. (Pubitemid 39006956)
84. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. 1996. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35:1067-1074.
85. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. 1997. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 36:1283-1289.
86. Taga T, Kishimoto T. 1997. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797-819. (Pubitemid 27169299)
87. Thanou-Stavraki A, Sawalha AH. 2011. An update on belimu-mab for the treatment of lupus. Biologics 5:33-43.
88. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. 2000. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85:207-214.
89. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. 2008. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 58:251-262.
90. Uhm WS, Na K, Song GW, Jung SS, Lee T, Park MH, Yoo DH. 2003. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 42:935-938. (Pubitemid 37220958)
91. Vereecke L, Beyaert R, van Loo G. 2009. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopa-thology. Trends Immunol 30:383-391.
92. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, Ziegler J, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Alarcon GS, Vila LM, Alarcon-Riquelme ME, James JA, Gilkeson GS, Jacob CO, Moser KL, Gaffney PM, Vyse TJ, Nath SK, Lipsky P, Harley JB, Sawalha AH. 2009. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 60:2402-2407.
93. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. 2010. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 30:45-52.
94. Yang J, Chu Y, Yang X, Gao D, Zhu L, Wan L, Li M. 2009. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60:1472-1483.
95. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. 2009. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60:1785-1796.
96. Ytterberg SR, Schnitzer TJ. 1982. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25:401-406. (Pubitemid 12158948)
97. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B, Gallo RC, Kou-touzov S. 2009. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare mu-rine model. Proc Natl Acad Sci USA 106:5294-5299.
98. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T. 2001. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10. (Pubitemid 32038409)
99. Zhang Z, Kyttaris VC, Tsokos GC. 2009. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 183:3160-3169.